Major M&A Bookends Year Of Mainly Steady Growth For Leading Medtech Groups
Executive Summary
In Vivo's latest rankings of the top 100 revenue earners in the medical technology industry show the groups leading the global market tightening their grip further in 2017. This was partly a function of providers choosing to partner more and more with fewer suppliers who can offer a wider provision of services. But it was steady as she goes for most of the multinational medtechs, with some major exceptions, and there will be more M&A reflected in next year's rankings, based on 2018 revenues.
You may also be interested in...
Bringing The Clinician's Rationale Into The Heart Of Strategic Decision-Making At Boston Scientific
Boston Scientific Corp. has been back on the M&A trail in a big way in 2018, with a succession of strategic additions of various sizes that all have potential patient and shareholder impact across – and beyond – its established divisions. Chief medical officer of 18 months Ian Meredith explains the thought processes driving this policy, and the added dimension a CMO can bring to the overall question of strategy.
UK Pro-Innovation Report Offers Promise For Medtech With MHRA/NICE Alignment
Report to government underlines need for faster, parallel evaluation of medtech and healthtech innovation and recommends bigger role for MHRA alongside work done by approved bodies on UKCA file processing.
News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests
This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.